Skip to main content
SpringerLink
Log in

SPECT/CT for Thyroid Cancer Imaging

  • Chapter
  • First Online:
Clinical Applications of SPECT-CT

  • 756 Accesses

Abstract

Considerable developments in nuclear medicine imaging technology have occurred in the past decade, with SPECT/CT obtained on hybrid gamma cameras with in-line CT proving to be a powerful diagnostic tool that allows for accurate anatomic localization and characterization of radioactivity distributions. SPECT/CT has substantially improved the interpretation of radioiodine scintigraphy for evaluation of well-differentiated thyroid cancer, using both post-therapeutic and diagnostic 131-I administered activities. SPECT/CT contributes to risk stratification and completion of staging by improved characterization of N and M scores. The information obtained from SPECT/CT impacts patient management and contributes important prognostic information. The new technology of SPECT/CT has significant potential to change the current management protocols and guidelines in thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  PubMed  Google Scholar 

  2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.

    Article  CAS  PubMed  Google Scholar 

  3. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25(10):1127–36.

    Article  PubMed  Google Scholar 

  4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83(12):2638–48.

    Article  CAS  PubMed  Google Scholar 

  5. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62(2):118–28.

    Article  PubMed  Google Scholar 

  6. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100(5):950–7.

    Article  PubMed  Google Scholar 

  7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gemsenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197(2):182–90.

    Article  PubMed  Google Scholar 

  9. Goropoulos A, Karamoshos K, Christodoulou A, Ntitsias T, Paulou K, Samaras A, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2004;28(12):1275–81.

    Article  PubMed  Google Scholar 

  10. Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(7):857–60.

    Article  PubMed  Google Scholar 

  11. Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and medullary thyroid cancer: surgical management of cervical lymph nodes. Clin Oncol (R Coll Radiol). 2017;29(5):283–9.

    Article  CAS  Google Scholar 

  12. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31–40.

    Article  PubMed  Google Scholar 

  13. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43–63.

    Article  CAS  PubMed  Google Scholar 

  14. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19(7):707–16.

    Article  CAS  PubMed  Google Scholar 

  15. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18(4):559–67; discussion 67–8.

    Article  CAS  PubMed  Google Scholar 

  16. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope. 2003;113(12):2102–7.

    Article  PubMed  Google Scholar 

  17. Wang TS, Dubner S, Sznyter LA, Heller KS. Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 2004;130(1):110–3.

    Article  PubMed  Google Scholar 

  18. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751–6.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018;68(1):55–63.

    Article  PubMed  Google Scholar 

  20. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461–70.

    Article  PubMed  Google Scholar 

  21. Lee SW. SPECT/CT in the treatment of differentiated thyroid cancer. Nucl Med Mol Imaging. 2017;51(4):297–303.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94(6):2075–84.

    Article  CAS  PubMed  Google Scholar 

  23. Barwick T, Murray I, Megadmi H, Drake WM, Plowman PN, Akker SA, et al. Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162(6):1131–9.

    Article  CAS  PubMed  Google Scholar 

  24. Blum M, Tiu S, Chu M, Goel S, Friedman K. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients. Thyroid. 2011;21(11):1235–47.

    Article  PubMed  Google Scholar 

  25. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49(12):1952–7.

    Article  PubMed  Google Scholar 

  26. Ciappuccini R, Heutte N, Trzepla G, Rame JP, Vaur D, Aide N, et al. Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011;164(6):961–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, et al. Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36(6):886–93.

    Article  CAS  PubMed  Google Scholar 

  28. Maruoka Y, Abe K, Baba S, Isoda T, Sawamoto H, Tanabe Y, et al. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology. 2012;265(3):902–9.

    Article  PubMed  Google Scholar 

  29. Menges M, Uder M, Kuwert T, Schmidt D. 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(6):555–60.

    Article  PubMed  Google Scholar 

  30. Mustafa M, Kuwert T, Weber K, Knesewitsch P, Negele T, Haug A, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur J Nucl Med Mol Imaging. 2010;37(8):1462–6.

    Article  CAS  PubMed  Google Scholar 

  31. Qiu ZL, Xu YH, Song HJ, Luo QY. Localization and identification of parapharyngeal metastases from differentiated thyroid carcinoma by 131I-SPECT/CT. Head Neck. 2011;33(2):171–7.

    Article  PubMed  Google Scholar 

  32. Ruf J, Lehmkuhl L, Bertram H, Sandrock D, Amthauer H, Humplik B, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25(12):1177–82.

    Article  PubMed  Google Scholar 

  33. Schmidt D, Linke R, Uder M, Kuwert T. Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation. Eur J Nucl Med Mol Imaging. 2010;37(4):699–705.

    Article  PubMed  Google Scholar 

  34. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50(1):18–23.

    Article  PubMed  Google Scholar 

  35. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50(2):184–90.

    Article  PubMed  Google Scholar 

  36. Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31(10):1435–42.

    Article  CAS  PubMed  Google Scholar 

  37. Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin Imaging. 2009;33(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  38. Wong KK, Avram AM. Posttherapy I-131 thymic uptake demonstrated with SPECT/CT in a young girl with papillary thyroid carcinoma. Thyroid. 2008;18(8):919–20.

    Article  PubMed  Google Scholar 

  39. Wong KK, Sisson JC, Koral KF, Frey KA, Avram AM. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR Am J Roentgenol. 2010;195(3):730–6.

    Article  PubMed  Google Scholar 

  40. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol. 2008;191(6):1785–94.

    Article  PubMed  Google Scholar 

  41. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009;82(982):860–76.

    Article  CAS  PubMed  Google Scholar 

  42. Yamamoto Y, Nishiyama Y, Monden T, Matsumura Y, Satoh K, Ohkawa M. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med. 2003;44(12):1905–10.

    PubMed  Google Scholar 

  43. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51(9):1361–7.

    Article  CAS  PubMed  Google Scholar 

  44. Wakabayashi H, Nakajima K, Fukuoka M, Inaki A, Nakamura A, Kayano D, et al. Double-phase (131)I whole body scan and (131)I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification. Ann Nucl Med. 2011;25(9):609–15.

    Article  PubMed  Google Scholar 

  45. Spanu A, Nuvoli S, Gelo I, Mele L, Piras B, Madeddu G. Role of diagnostic (131)I SPECT/CT in long-term follow-up of patients with papillary thyroid microcarcinoma. J Nucl Med. 2018;59(10):1510–5.

    Article  PubMed  Google Scholar 

  46. Malamitsi JV, Koutsikos JT, Giourgouli SI, Zachaki SF, Pipikos TA, Vlachou FJ, et al. I-131 postablation SPECT/CT predicts relapse of papillary thyroid carcinoma more accurately than whole body scan. In Vivo. 2019;33(6):2255–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Lee CH, Jung JH, Son SH, Hong CM, Jeong JH, Jeong SY, et al. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer. PLoS One. 2018;13(8):e0202644.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Avram AM. Role of SPECT/CT, versus traditional practices, in individualizing treatment of thyroid carcinoma: reply. J Nucl Med. 2012;53(11):1819.

    Article  Google Scholar 

  49. Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012;53(5):754–64.

    Article  PubMed  Google Scholar 

  50. Barwick TD, Dhawan RT, Lewington V. Role of SPECT/CT in differentiated thyroid cancer. Nucl Med Commun. 2012;33(8):787–98.

    Article  CAS  PubMed  Google Scholar 

  51. Toubert ME, Vija L, Vercellino L, Banayan S, Faugeron I, Berenger N, et al. Additional diagnostic value of hybrid SPECT-CT systems imaging in patients with differentiated thyroid cancer. Am J Clin Oncol. 2014;37(3):305–13.

    Article  PubMed  Google Scholar 

  52. Xue YL, Qiu ZL, Song HJ, Luo QY. Value of (131)I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature. Eur J Nucl Med Mol Imaging. 2013;40(5):768–78.

    Article  CAS  PubMed  Google Scholar 

  53. Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42(7):998–1004.

    CAS  PubMed  Google Scholar 

  54. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21(3):231–6.

    Article  PubMed  Google Scholar 

  55. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112(6):1139–46; discussion 46–7.

    CAS  PubMed  Google Scholar 

  56. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–7; discussion 7–8.

    Article  PubMed  Google Scholar 

  57. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;19(10):1043–8.

    Article  PubMed  Google Scholar 

  58. Strate SM, Lee EL, Childers JH. Occult papillary carcinoma of the thyroid with distant metastases. Cancer. 1984;54(6):1093–100.

    Article  CAS  PubMed  Google Scholar 

  59. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol. 2008;68(1):108–16.

    Article  CAS  Google Scholar 

  60. Szujo S, Sira L, Bajnok L, Bodis B, Gyory F, Nemes O, et al. The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. Oncotarget. 2017;8(45):79825–34.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med. 2009;39(5):308–40.

    Article  PubMed  Google Scholar 

  62. Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39(9):1542–6.

    CAS  PubMed  Google Scholar 

  63. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006;36(3):194–205.

    Article  PubMed  Google Scholar 

  64. van Sorge-van Boxtel RA, van Eck-Smit BL, Goslings BM. Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Commun. 1993;14(5):365–72.

    Article  Google Scholar 

  65. Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab. 2013;98(3):1163–71.

    Article  CAS  PubMed  Google Scholar 

  66. Van Nostrand D, Aiken M, Atkins F, Moreau S, Garcia C, Acio E, et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(8):849–55.

    Article  PubMed  Google Scholar 

  67. Mitchell G, Pratt BE, Vini L, McCready VR, Harmer CL. False positive 131I whole body scans in thyroid cancer. Br J Radiol. 2000;73(870):627–35.

    Article  CAS  PubMed  Google Scholar 

  68. Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30(2):115–32.

    Article  CAS  PubMed  Google Scholar 

  69. Dumcke CW, Madsen JL. Usefulness of SPECT/CT in the diagnosis of intrathoracic goiter versus metastases from cancer of the breast. Clin Nucl Med. 2007;32(2):156–9.

    Article  PubMed  Google Scholar 

  70. Jong I, Taubman K, Schlicht S. Bronchiectasis simulating pulmonary metastases on iodine-131 scintigraphy in well-differentiated thyroid carcinoma. Clin Nucl Med. 2005;30(10):688–9.

    Article  PubMed  Google Scholar 

  71. Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus: value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions. Thyroid. 2007;17(9):901–2.

    Article  PubMed  Google Scholar 

  72. Jammah AA, Driedger A, Rachinsky I. Incidental finding of ovarian teratoma on post-therapy scan for papillary thyroid cancer and impact of SPECT/CT imaging. Arq Bras Endocrinol Metabol. 2011;55(7):490–3.

    Article  PubMed  Google Scholar 

  73. Mebarki M, Menemani A, Medjahedi A, Boualou F, Slama A, Ouguirti S, et al. Radioiodine accumulation in a giant ovarian cystadenofibroma detected incidentally by 131-I whole body scans. Case Rep Radiol. 2012;2012:295617.

    PubMed  PubMed Central  Google Scholar 

  74. Sakahara H, Yamashita S, Suzuki K, Imai M, Kosugi T. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer. Ann Nucl Med. 2007;21(9):525–7.

    Article  PubMed  Google Scholar 

  75. Savas H, Wong KK, Saglik B, Hubers D, Ackermann RJ, Avram AM. SPECT/CT characterization of oral activity on radioiodine scintigraphy. J Clin Endocrinol Metab. 2013;98(11):4410–6.

    Article  CAS  PubMed  Google Scholar 

  76. Albano D, Motta F, Baronchelli C, Lucchini S, Bertagna F. 131I whole-body scan incidental uptake due to spermatocele. Clin Nucl Med. 2017;42(11):901–4.

    Article  PubMed  Google Scholar 

  77. Jang HY, Kim BH, Kim WJ, Jeon YK, Kim SS, Kim YK, et al. False-positive radioiodine uptake in a functional ovarian cyst in a patient treated with total thyroidectomy for papillary cancer. Intern Med. 2013;52(20):2321–3.

    Article  PubMed  Google Scholar 

  78. Rizzo A, Zagaria L, Perotti G, Annunziata S, Salvatori M. Accumulation of 131I in esophageal diverticulum diagnosed by SPECT/CT. Clin Nucl Med. 2018;43(11):e410–e1.

    Article  PubMed  Google Scholar 

  79. Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging. 2012;2(3):362–85.

    PubMed  PubMed Central  Google Scholar 

  80. Glazer DI, Brown RK, Wong KK, Savas H, Gross MD, Avram AM. SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiographics. 2013;33(2):397–418.

    Article  PubMed  Google Scholar 

  81. Agriantonis DJ, Hall L, Wilson MA. Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer. Clin Nucl Med. 2009;34(4):247–8.

    Article  PubMed  Google Scholar 

  82. Aide N, Lehembre E, Gervais R, Bardet S. Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation. Thyroid. 2007;17(12):1305–6.

    Article  PubMed  Google Scholar 

  83. Qiu ZL, Luo QY. Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med. 2009;34(3):137–40.

    Article  PubMed  Google Scholar 

  84. von Falck C, Beer G, Gratz KF, Galanski M. Renal metastases from follicular thyroid cancer on SPECT/CT. Clin Nucl Med. 2007;32(9):751–2.

    Article  Google Scholar 

  85. Zhao LX, Li L, Li FL, Zhao Z. Rectus abdominis muscle metastasis from papillary thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med. 2010;35(5):360–1.

    Article  PubMed  Google Scholar 

  86. Barwick T, Murray I, Megadmi H, Drake W, Plowman PN, Akker S, et al. SPECT/CT using Iodine-123 in patients with differentiated thyroid cancer—additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162(6):1131–9.

    Article  CAS  PubMed  Google Scholar 

  87. Wong KK, Sisson JC, Koral KF, Frey KA, Avram AM. Staging of differentiated thyroid carcinoma using diagnostic 131-I SPECT-CT. AJR Am J Roentgenol. 2010;195(3):730–6.

    Article  PubMed  Google Scholar 

  88. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.

    Article  CAS  PubMed  Google Scholar 

  89. Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab. 2015;100(5):1895–902.

    Article  CAS  PubMed  Google Scholar 

  90. Qiu ZL, Xue YL, Song HJ, Luo QY. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun. 2012;33(12):1232–42.

    Article  CAS  PubMed  Google Scholar 

  91. Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, et al. Comparison of (1)(3)(1)I whole-body imaging, (1)(3)(1)I SPECT/CT, and (1)(8)F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(8):1459–68.

    Article  PubMed  Google Scholar 

  92. Bulzacka I, Makarewicz J. Postablative 131I SPECT/CT is much more sensitive than cervical ultrasonography for the detection of thyroid remnants in patients after total thyroidectomy for differentiated thyroid cancer. Clin Nucl Med. 2020;45(12):948–53.

    Article  PubMed  Google Scholar 

  93. Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. Thyroid. 2009;19(3):297–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47(12):1985–94.

    CAS  PubMed  Google Scholar 

  95. Buck AK, Nekolla SG, Ziegler SI, Drzezga A. SPECT/CT. J Nucl Med. 2008;49(8):1305–19.

    Article  PubMed  Google Scholar 

  96. Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med. 2007;37(5):391–8.

    Article  PubMed  Google Scholar 

  97. Kim HY, Gelfand MJ, Sharp SE. SPECT/CT imaging in children with papillary thyroid carcinoma. Pediatr Radiol. 2011;41(8):1008–12.

    Article  PubMed  Google Scholar 

  98. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28(5):639–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

None.

Disclosure Statement: The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Anca M. Avram

  2. Nuclear Medicine/Radiology Department, Feinberg School of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, IL, USA

    Hatice Savas

Authors
  1. Anca M. Avram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hatice Savas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anca M. Avram .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany

    Hojjat Ahmadzadehfar

  2. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

    Hans-Jürgen Biersack

  3. Deptartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany

    Ken Herrmann

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Avram, A.M., Savas, H. (2022). SPECT/CT for Thyroid Cancer Imaging. In: Ahmadzadehfar, H., Biersack, HJ., Herrmann, K. (eds) Clinical Applications of SPECT-CT. Springer, Cham. https://doi.org/10.1007/978-3-030-65850-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-65850-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-65849-6

  • Online ISBN: 978-3-030-65850-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation